SARS-CoV-2 (COVID-19) Spike RBD Neutralizing Antibody [C-A11]

Background:

This antibody recognizes the SARS-CoV-2 spike protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule 1; Sia, sialic acid; O-ac Sia, and O-acetylated sialic acid. The spike protein is essential for both host specificity and viral infectivity. The term ‘peplomer’ is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It’s been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the spike protein are summarized as: mediates receptor binding and membrane fusion, defines the range of the hosts and specificity of the virus; main component to bind with the neutralizing antibody; key target for vaccine design; and can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate.